Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan.
Publication
, Journal Article
Alder, L; Trapani, D; Bradbury, C; Van Swearingen, AED; Tolaney, SM; Khasraw, M; Anders, CK; Lascola, CD; Hsu, L; Lin, NU; Sammons, S
Published in: Npj Breast Cancer
March 30, 2023
Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Npj Breast Cancer
DOI
ISSN
2374-4677
Publication Date
March 30, 2023
Volume
9
Issue
1
Start / End Page
19
Location
United States
Citation
APA
Chicago
ICMJE
MLA
NLM
Alder, L., Trapani, D., Bradbury, C., Van Swearingen, A. E. D., Tolaney, S. M., Khasraw, M., … Sammons, S. (2023). Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. Npj Breast Cancer, 9(1), 19. https://doi.org/10.1038/s41523-023-00519-0
Alder, Laura, Dario Trapani, Claire Bradbury, Amanda E. D. Van Swearingen, Sara M. Tolaney, Mustafa Khasraw, Carey K. Anders, et al. “Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan.” Npj Breast Cancer 9, no. 1 (March 30, 2023): 19. https://doi.org/10.1038/s41523-023-00519-0.
Alder L, Trapani D, Bradbury C, Van Swearingen AED, Tolaney SM, Khasraw M, et al. Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. Npj Breast Cancer. 2023 Mar 30;9(1):19.
Alder, Laura, et al. “Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan.” Npj Breast Cancer, vol. 9, no. 1, Mar. 2023, p. 19. Pubmed, doi:10.1038/s41523-023-00519-0.
Alder L, Trapani D, Bradbury C, Van Swearingen AED, Tolaney SM, Khasraw M, Anders CK, Lascola CD, Hsu L, Lin NU, Sammons S. Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. Npj Breast Cancer. 2023 Mar 30;9(1):19.
Published In
Npj Breast Cancer
DOI
ISSN
2374-4677
Publication Date
March 30, 2023
Volume
9
Issue
1
Start / End Page
19
Location
United States